ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2793

BMP2 Requires TGF-Beta to Induce Osteophytes during Experimental Osteoarthritis

Esmeralda Blaney Davidson1, Arjen Blom2, Arjan van Caam1, Elly Vitters2, Miranda Bennink1, Wim van den Berg2, Fons van de Loo3 and Peter van der Kraan4, 1Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, 2Experimental Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, 3Rheumatology, Radboud university medical center, Nijmegen, Netherlands, 4Radboud University Medical Center, Nijmegen, Netherlands

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Animal models, growth factors, osteoarthritis and osteophytosis

  • Tweet
  • Email
  • Print
Session Information

Title: Biology and Pathology of Bone and Joint I: Bone Remodeling in Inflammation and Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose:
Osteophytes are a major hallmark of osteoarthritis (OA). Both TGF-beta and BMP2 can induce osteophytes in murine knee joints. We demonstrated that TGF-beta could induce chondrogenesis in mesenchymal stem cells when BMPs were inhibited but not vice versa. This suggested that BMP2 might require a trigger like TGF-beta to induce initial stages of chondrogenesis. Therefore, we investigated whether BMP2 was still able to induce osteophyte formation in experimental OA when TGF-beta activity was blocked.

Methods:

We made a unique transgenic mouse (Col2a1-rtTA-BMP2) expressing BMP2 under control of the Col2a1 promoter, only when exposed to doxycycline (dox) which results in only chondrocytes producing BMP2. These mice were fed dox-food up to 8 weeks to investigate BMP2 effects on osteophyte formation. We induced the DMM-model and investigated whether BMP2 augmented osteophyte formation. We combined the DMM-model with intra-articular injection of an adenovirus overexpressing TGF-beta-inhibitor LAP with or without dox. Knee joints were isolated 4 weeks after DMM for histology.

Results:

There was no significant difference in osteophyte formation between dox and non-dox treated Col2a1-rtTA-BMP2 mice. However, dox treatment increased the number of osteophytes (8.0) during DMM compared to DMM non-dox (4.25). These “new” osteophytes were Iarger than DMM-induced osteophytes. The lack of osteophytes by dox compared to DMM+dox implied that DMM provided a trigger enabling BMP2-induced osteophyte formation. To investigate whether  TGF-beta was that trigger, we injected Ad-LAP one day after DMM-induction. Without TGF-beta, BMP2 no longer augmented the number of osteophytes during DMM. Strikingly, inhibition of TGF-beta significantly reduced the pace of osteophyte formation.. This was completely abolished by the presence of BMP2 restoring the speed of osteophyte formation and maturation.

2013 OARSI osteophytes.jpg

Conclusion:

Our data show that BMP2 is capable of inducing osteophyte formation, but is dependent on an additional trigger to achieve this, as present in OA. In OA conditions, BMP2 can severely aggravate osteophyte formation, both in number and size. However, when TGF-beta is blocked BMP2 is no longer capable of aggravating osteophyte formation during DMM. Strikingly, early inhibition of TGF-beta during OA impaired the speed of osteophyte formation, which could be compensated by the presence of BMP2. Our data show for the first time that BMP2 is dependent on TGF-beta to induce de novo osteophyte formation. This provides novel insight into the mechanism behind osteophyte formation and provides clues for future therapeutic application for osteophyte formation in OA.


Disclosure:

E. Blaney Davidson,
None;

A. Blom,
None;

A. van Caam,
None;

E. Vitters,
None;

M. Bennink,
None;

W. van den Berg,
None;

F. van de Loo,
None;

P. van der Kraan,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/bmp2-requires-tgf-beta-to-induce-osteophytes-during-experimental-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology